Cosmo (SWX:COPN) is back in focus after reporting half year 2026 results, with lower sales of €50.24 million and a higher net loss of €4.75 million compared with the prior year period. See our latest analysis for Cosmo. Despite the weaker half year result, Cosmo’s recent 1 day share price return of 7.82% and 7 day share price return of 9.37% suggest short term momentum is improving. However, the year to date share price return is still down 34.63% and the 5 year total shareholder return is...

Cosmo (SWX:COPN) announced that its commercial partner Glenmark Specialty has launched Winlevi in key European markets. The launch follows EU marketing authorization for Winlevi as a first in class topical androgen receptor inhibitor for acne treatment. This is a material step in Cosmo's European dermatology expansion and product commercialization plans. For you as an investor, Winlevi adds another branded product route for Cosmo (SWX:COPN) in dermatology, an area where new mechanisms of...

If you are wondering whether Cosmo Pharmaceuticals' current share price still offers value after a strong run, this article walks through what the numbers actually say about the stock. The share price closed at CHF 90.30 recently, with a 1 year return of 75.2% even after short term pullbacks of 16.9% over 7 days, 23.2% over 30 days and 14.3% year to date. Recent price moves sit against a backdrop of ongoing interest in the pharmaceuticals and biotech space, as investors weigh individual...

Cosmo Pharmaceuticals NV (CMOPF) reports robust revenue growth, strategic advancements, and a solid cash position, setting the stage for future expansion.

Cosmo Pharmaceuticals (SWX:COPN) has been drawing attention after a very large total return over the past 3 years, prompting investors to reassess how its gastroenterology and dermatology portfolio fits into their healthcare exposure. See our latest analysis for Cosmo Pharmaceuticals. After a sharp 76.6% 90 day share price return and a 76.5% total shareholder return over the past year, Cosmo Pharmaceuticals’ recent 2.5% single day share price decline to CHF116.2 hints at investors reassessing...

Cosmo Pharmaceuticals' (VTX:COPN) stock is up by a considerable 55% over the past three months. Since the market...

Cosmo Pharmaceuticals recently reported successful Phase III results for its Clascoterone 5% solution in male hair loss and secured European Commission marketing authorization, via its partner Glenmark Pharmaceuticals, for Winlevi (clascoterone 10 mg/g cream) to treat acne vulgaris across 17 countries. Together, these milestones suggest Cosmo is extending the reach of its clascoterone franchise across two large dermatology indications, potentially reinforcing its position as an...

Cosmo's stunning late-stage trial results could unlock a multibillion-dollar market with billions of potential customers worldwide.

Shares of Cosmo Pharmaceuticals (SWX:COPN) have drawn interest lately as investors take a closer look at its recent performance. Over the past month, the stock is down 2%, but it remains up 17% for the past 3 months. See our latest analysis for Cosmo Pharmaceuticals. Looking at the bigger picture, Cosmo Pharmaceuticals’ share price return shows clear momentum. A hefty 17.3% gain over the last 90 days stands out against a modest 6% total shareholder return for the past year. Recent price...

Key Insights The considerable ownership by private companies in Cosmo Pharmaceuticals indicates that they collectively...